LAMPA

LAMPA
Clinical data
Other names	LMP; LAMP; N-Methyl-N-propyllysergamide;
Legal status
Legal status	US: Schedule I (isomer of LSD);
Identifiers
	IUPAC name N,7-dimethyl-N-propyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	40158-98-3;
PubChem CID	613620;
ChemSpider	533384;
CompTox Dashboard (EPA)	DTXSID701043313 ;
Chemical and physical data
Formula	C20H25N3O
Molar mass	323.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;
	InChI InChI=InChI=1S/C20H25N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h5-7,9,11,14,18,21H,4,8,10,12H2,1-3H3; Key:CZRJGQXHVRNZRZ-UHFFFAOYSA-N;

Lysergic acid methylpropylamide (LAMPA, LAMP, or LMP), also known as N-methyl-N-propyllysergamide, is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism. In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 μg. It shows reduced-efficacy partial agonism of the serotonin 5-HT_2A receptor relative to LSD, which may be responsible for its equivocal hallucinogenic effects.